You’ve probably heard that movement can be part of a weight-management plan. But what happens when researchers test exercise and a GLP-1 medicine together?
One randomized study asked that question using liraglutide. Its design is useful because the combination was compared with exercise, medicine and placebo as separate strategies. The results are informative, but the study routine was specific and should not be copied as a personal prescription.
The starting point matters
Adults with obesity and without diabetes began with an eight-week, supervised low-calorie diet. Of the 215 people who started it, 195 achieved the study’s initial weight-loss requirement and were randomized.
That means the one-year comparison began after participants had already lost weight. It was a study of maintaining and changing weight after that initial period, not a test of starting a GLP-1 and exercise from any starting point.
The study diet was part of a monitored research protocol. It is not an instruction for readers to follow an extremely restrictive diet. If you’re considering changes to eating, discuss a suitable approach with your care team.
Four groups, one year
The randomized participants were assigned to an exercise program plus placebo, liraglutide with usual activity, both exercise and liraglutide, or placebo with usual activity. The exercise program involved moderate-to-vigorous aerobic activity with organized support.
That support matters. A study program can include monitoring, visits and access that may look very different from trying to squeeze a walk into a busy workday. It’s useful to ask what help participants received before assuming a result came from a medicine alone.
In this trial, an exercise instructor helped plan and monitor individual programs. Participants were encouraged to combine supervised group sessions with activity on their own, and they wore heart-rate monitors during exercise. That structure is part of what was tested; it isn’t a requirement for your own routine.
What happened to weight?
After a year, each active strategy had a greater average weight reduction than placebo. The combination produced greater weight reduction than exercise alone. Its difference from liraglutide alone on that weight measure was not statistically significant.
The combination also reduced body-fat percentage more than either single strategy in the reported comparison. Weight and body-fat percentage are different outcomes, so it’s important not to swap one result for the other.
These are averages for people in one study. They don’t set a deadline or a required number for your own treatment, and they don’t establish that a different medicine and different routine will produce identical results.
What does it say about exercise?
The study supports looking at the whole plan, including the kind of activity and support offered. It does not mean everyone must exercise at the same intensity. Your starting fitness, joints, balance, schedule and health conditions matter.
For some people a comfortable walk is a place to begin. Others may already have a routine and want to add suitable strength work. Our guide to cardio and strength training on a GLP-1 discusses how different kinds of movement can fit together.
If pain, dizziness, unusual breathlessness or digestive symptoms make activity difficult, talk with your care team about adjusting the plan. The goal is a routine that works with your life and health, not one that looks impressive for a week.
Questions to ask when reading a trial
Look for the medicine used, the study population, the starting point and the comparison. Was the exercise supervised? Did everyone get the same support? Was the outcome weight, body composition, fitness or something else?
Those questions help keep a useful finding in proportion. A combined strategy can be worth discussing without turning one research protocol into a rule for everyone.